Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc

Bullboard Posts

Comment by rjc7on Oct 29, 2014 12:47pm

133 Views

Post# 23072581

RE:RE:RE:RE:Making a clean break

I doubt it. From what I understand, after the "first run" of vaccine production, there is a lot of waste that would normally be disposed of. There is still sufficeint virus left in the waste that can be extracted and purified to produce more vaccine when used with Virusmax technology.

Bullboard Posts

Anaergia expands relationship with PepsiCo